SpecificityThe mouse monoclonal antibody VIM8 recognizes human CD65, an asialo-fucoganglioside expressed on the surface of peripheral blood granulocytes (highly) and monocytes (weakly).
WorkshopHLDA II: WS Code M 27; HLDA III: WS Code M 261; HLDA IV: WS Code M 23; HLDA V: WS Code MA095, MA096; HLDA VI: WS Code MR12
ApplicationFC (QC tested)
Application detailsFlow cytometry: The reagent is designed for analysis of human blood cells using 10 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
Other namesceramide-dodecasaccharide, type II fucoganglioside
PreparationThe purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
FormulationStabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide
Storage and handlingStore in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Exbio licence noteThe product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden.Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Product specific references:
Kniep B, Peter-Katalinic J, Müthing J, Majdic O, Pickl WF, Knapp W: The CDw65 monoclonal antibodies VIM-8 and VIM-11 bind to the neutral glycolipid V3FucnLc8Cer. J Biochem. 1996 Mar;119(3):456-62.PubMed
Paietta E, Neuberg D, Bennett JM, Dewald G, Rowe JM, Cassileth PA, Cripe L, Tallman MS, Wiernik PH and the Eastern Cooperative Oncology Group: Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials. Leukemia. 2003 Aug;17(8):1544-50.PubMed